Utomilumab
- Generic Name
- Utomilumab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1417318-27-4
- Unique Ingredient Identifier
- 6YY8O697VF
- Background
Utomilumab is under investigation in clinical trial NCT03318900 (T Cell Immunotherapy for Advanced Ovarian Cancer).
- Associated Conditions
- -
- Associated Therapies
- -
A Study Of 4-1BB Agonist PF-05082566 Plus PD-1 Inhibitor MK-3475 In Patients With Solid Tumors (B1641003/KEYNOTE-0036)
- First Posted Date
- 2014-07-02
- Last Posted Date
- 2019-02-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 23
- Registration Number
- NCT02179918
- Locations
- 🇺🇸
Research Administration Office, Los Angeles, California, United States
🇺🇸Ronald Reagan UCLA Medical Center, Drug Information Center, Los Angeles, California, United States
🇺🇸UCLA Hematology-Oncology Clinic, Los Angeles, California, United States
A Study Of PF-05082566 As A Single Agent And In Combination With Rituximab
- First Posted Date
- 2011-03-02
- Last Posted Date
- 2020-03-17
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 190
- Registration Number
- NCT01307267
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸UC San Diego Moores Cancer Center-Investigational Drug Services, La Jolla, California, United States
🇺🇸UC San Diego Medical Center-La Jolla (Jacobs Medical Center/Thornton Hospital), La Jolla, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath